Publication:
The effect of low HER2 expression on treatment outcomes in metastatic hormone receptor positive breast cancer patients treated with a combination of a CDK4/6 inhibitor and endocrine therapy: A multicentric retrospective study

Simple item page
dc.contributor.authorSARI, MURAT
dc.contributor.authorsÇALIŞKAN YILDIRIM E., ATAĞ E., Coban E., Umit Unal O., Celebi A., Keser M., UZUN M., KESKİNKILIÇ M., Tanrikulu Simsek E., Sari M., et al.
dc.date.accessioned2023-07-11T12:31:25Z
dc.date.available2023-07-11T12:31:25Z
dc.date.issued2023-08-01
dc.description.abstractBackground: CDK4/6 inhibitors combined with endocrine therapy have significantly improved treatment outcomes for metastatic hormone receptor-positive (HR+) breast cancer patients. However, the impact of low HER2 expression on treatment response and progression-free survival (PFS) remains unclear. Methods: This multicenter retrospective study included 204 HR+ breast cancer patients treated with a combination of CDK4/6 inhibitor and endocrine therapy. HER2-zero disease was detected in 138 (68%) and HER2-low disease in 66 (32%) patients. Treatment-related characteristics and clinical outcomes were analyzed, with a median follow-up of 22 months. Results: The objective response rate (ORR) was 72.7% in the HER2 low group and 66.6% in the HER2 zero group (p = 0.54). Median PFS was not significantly different between the HER2-low and HER2 zero groups (19 months vs.18 months, p = 0.89), although there was a trend toward longer PFS in the HER2-low group for first-line treatment (24 months progression-free survival rate 63% vs 49%). In recurrent disease, the median PFS was 25 months in the HER2-low group and 12 months in the HER2-zero group (p = 0.08), while in de novo metastatic disease, the median PFS was 18 months in the HER2-low group and 27 months in the HER2-zero group (p = 0.16). The order of CDK4/6 inhibitor use and the presence of visceral metastasis were identified as independent variables affecting PFS. Conclusion: Low HER2 expression did not significantly impact treatment response or PFS in HR+ breast cancer patients treated with a CDK4/6 inhibitor and endocrine therapy. Because of the conflicting results in the literature, further prospective studies are needed to evaluate the clinical significance of HER2 expression in HR+ breast cancer.
dc.identifier.citationÇALIŞKAN YILDIRIM E., ATAĞ E., Coban E., Umit Unal O., Celebi A., Keser M., UZUN M., KESKİNKILIÇ M., Tanrikulu Simsek E., Sari M., et al., "The effect of low HER2 expression on treatment outcomes in metastatic hormone receptor positive breast cancer patients treated with a combination of a CDK4/6 inhibitor and endocrine therapy: A multicentric retrospective study", Breast, cilt.70, ss.56-62, 2023
dc.identifier.doi10.1016/j.breast.2023.06.006
dc.identifier.endpage62
dc.identifier.issn0960-9776
dc.identifier.startpage56
dc.identifier.urihttps://www.scopus.com/inward/record.uri?partnerID=HzOxMe3b&scp=85162048928&origin=inward
dc.identifier.urihttps://hdl.handle.net/11424/291151
dc.identifier.volume70
dc.language.isoeng
dc.relation.ispartofBreast
dc.rightsinfo:eu-repo/semantics/openAccess
dc.subjectTıp
dc.subjectDahili Tıp Bilimleri
dc.subjectİç Hastalıkları
dc.subjectOnkoloji
dc.subjectCerrahi Tıp Bilimleri
dc.subjectYaşam Bilimleri
dc.subjectMoleküler Biyoloji ve Genetik
dc.subjectSitogenetik
dc.subjectSağlık Bilimleri
dc.subjectTemel Bilimler
dc.subjectMedicine
dc.subjectInternal Medicine Sciences
dc.subjectInternal Diseases
dc.subjectOncology
dc.subjectSurgery Medicine Sciences
dc.subjectLife Sciences
dc.subjectMolecular Biology and Genetics
dc.subjectCytogenetic
dc.subjectHealth Sciences
dc.subjectNatural Sciences
dc.subjectKlinik Tıp (MED)
dc.subjectYaşam Bilimleri (LIFE)
dc.subjectKlinik Tıp
dc.subjectCERRAHİ
dc.subjectONKOLOJİ
dc.subjectBİYOKİMYA VE MOLEKÜLER BİYOLOJİ
dc.subjectClinical Medicine (MED)
dc.subjectLife Sciences (LIFE)
dc.subjectCLINICAL MEDICINE
dc.subjectMOLECULAR BIOLOGY & GENETICS
dc.subjectSURGERY
dc.subjectONCOLOGY
dc.subjectBIOCHEMISTRY & MOLECULAR BIOLOGY
dc.subjectCerrahi
dc.subjectKanser Araştırmaları
dc.subjectSurgery
dc.subjectCancer Research
dc.subjectbreast cancer
dc.subjectHER2-Low
dc.subjecthormone positive
dc.subjectpalbociclib
dc.subjectribociclib
dc.titleThe effect of low HER2 expression on treatment outcomes in metastatic hormone receptor positive breast cancer patients treated with a combination of a CDK4/6 inhibitor and endocrine therapy: A multicentric retrospective study
dc.typearticle
dspace.entity.typePublication
local.avesis.id196062f2-22e7-49eb-ab26-9a1cdf4a559c
local.indexed.atPUBMED
local.indexed.atSCOPUS
relation.isAuthorOfPublication0bbf9e5a-bf3e-4645-9f2d-1e1de92915d0
relation.isAuthorOfPublication.latestForDiscovery0bbf9e5a-bf3e-4645-9f2d-1e1de92915d0

Files

Original bundle
Now showing 1 - 1 of 1
Thumbnail Image
Name:
67.pdf
Size:
1.7 MB
Format:
Adobe Portable Document Format
Download

Collections

Research Outputs